2026-01-11 - Analysis Report
# 1. Quick‑look Snapshot

| Metric | Value |
|--------|-------|
| Cumulative return (LRCX) | **+306.49 %** |
| Cumulative return (VOO) | **+94.03 %** |
| Divergence (LRCX vs VOO) | **+212.5 %** (top of historical range) |
| Relative divergence | **100 %** (current position in the past 0‑212.5 % band) |

**Takeaway:** Lam Research has outperformed the S&P 500 by a *huge* margin, with a cumulative gain that sits at the very top of its historical divergence band. This suggests a strong, long‑term growth trajectory relative to the benchmark.

---

# 2. Alpha‑Beta Snapshot (2016‑2025)

- **CAGR trend:** From modest 1 % (2016‑18) to a spectacular 150 % (2023‑25).  
- **MDD (maximum drawdown):** Consistently 34‑49 % in the earlier periods, but spikes to 49 % (2020‑22) and 42 % (2022‑24).  
- **Alpha:** Positive across all windows, peaking at **+88 %** (2023‑25).  
- **Beta:** Extremely high—rising from 17.2 (2016‑18) to a peak of **215.9** (2023‑25).  
- **Interpretation:** The stock delivers exceptional excess returns but is highly volatile relative to the market, reflecting a high‑growth, high‑risk profile.

---

# 3. Current Price Action & Technical Signals

| Indicator | Value |
|-----------|-------|
| Close | **$218.36** |
| 5‑day SMA | **$204.82** |
| 20‑day SMA | **$179.23** |
| 60‑day SMA | **$162.45** |
| RSI | **83.69** (over‑bought) |
| PPO | **+1.88 %** |
| Market Risk Indicator (MRI) | **0.7** (Medium risk) |

**Short commentary**

- The price is **well above** both the 5‑ and 20‑day moving averages, signaling a bullish trend.  
- RSI over 70 signals over‑bought territory; a pullback may be expected.  
- PPO shows a modest positive momentum.  
- MRI at 0.7 suggests a *medium* risk level—caution for very risk‑averse investors.  

**Expected return**  
- **11.1 %** over the long term (2+ years) vs. S&P 500.  
- Recent 20‑day relative divergence is flat, but the 7‑day rank is climbing, hinting at a possible short‑term upswing.

---

# 4. Recent News & Events (Jan 2026)

- **Jan 9 2026 –** *Lam Research soars today* (Yahoo Finance) – highlights a sharp rebound after a brief dip.  
- **Jan 11 2026 –** *Mizuho PT hike fuels 8.7 % surge* (Meyka) – positive analyst rating shift.  
- **Jan 11 2026 –** *Bayforest Capital invests in LRCX* (MarketBeat) – institutional endorsement.  
- **Jan 9 2026 –** *LRCX up 8 % today* (Quiver Quantitative) – market consensus of rally.  
- **Jan 6 2026 –** *Lam Research trading up* (The Globe and Mail) – commentary on strong earnings outlook.  
- **Dec 22 2025 –** *Lam Research a solid growth stock?* (Nasdaq) – independent validation of growth potential.

*Key theme:* Consistent media coverage points to strong earnings momentum and positive institutional sentiment.

---

# 5. Analyst Consensus

- **Recommendation:** **Buy**  
- **Mean rating:** **1.77** (1 = Strong Buy)  
- **Target price:** **$177.80** (avg) / **$265.00** (high) / **$115.00** (low)  
- **Recent rating changes:** No major revisions reported in the last 4 quarters.  

*Implication:* Analysts are generally bullish, with a target that comfortably exceeds the current price, but the upside range suggests some caution regarding valuation.

---

# 6. Earnings History (Latest Q4‑2025 to Q4‑2024)

| 날짜 (YYYY‑MM‑DD) | EPS | 매출 (B$) |
|------------------|-----|-----------|
| 2025‑10‑24 | 1.24 | 5.32 |
| 2025‑04‑25 | 1.04 | 4.72 |
| 2025‑01‑31 | 0.93 | 4.38 |
| 2024‑10‑28 | 0.86 | 4.17 |
| 2024‑07‑31 | 0.86 | 4.17 |

**Analysis**

- **EPS growth:** From $0.86 (Q4‑24) to $1.24 (Q4‑25) – a **+44 %** YoY jump.  
- **Revenue growth:** $4.17 B → $5.32 B, a **+27 %** YoY increase.  
- **Trend:** Strong earnings momentum with consistent revenue expansion; suggests robust demand for semiconductor equipment.

---

# 7. Quarterly Financial Health (2025‑09‑30 to 2024‑09‑30)

## Revenue & Profitability

| Quarter | Revenue (B$) | Profit Margin |
|---------|--------------|---------------|
| 2025‑09‑30 | $5.32 | 50.43 % |
| 2025‑06‑30 | $5.17 | 50.08 % |
| 2025‑03‑31 | $4.72 | 49.02 % |
| 2024‑12‑31 | $4.38 | 47.37 % |
| 2024‑09‑30 | $4.17 | 48.05 % |

*Observations:*  
- Revenue rising steadily; margin stays above 47 %—excellent profitability.  
- Consistent operating efficiency indicates strong cost controls.

## Capital & Leverage

| Quarter | Equity (B$) | ROE |
|---------|-------------|-----|
| 2025‑09‑30 | $10.19 | 15.39 % |
| 2025‑06‑30 | $9.86 | 17.44 % |
| 2025‑03‑31 | $9.51 | 13.99 % |
| 2024‑12‑31 | $8.81 | 13.52 % |
| 2024‑09‑30 | $8.47 | 13.18 % |

*Key points:*  
- Equity base growing, supporting a solid ROE (~15 %).  
- No excessive leverage; the company remains financially healthy.

---

# 8. Final Summary

- **Growth Engine:** Lam Research continues to deliver explosive cumulative returns (+306 %) far outpacing the market (+94 %).  
- **Technical Outlook:** Bullish trend with price well above moving averages; RSI over‑bought signals a short‑term correction might come, but strong momentum (PPO) and medium MRI keep the upside plausible.  
- **Fundamental Strength:** Revenue and earnings are on a clear uptrend, margins > 50 %, and ROE ≈ 15 %.  
- **Market Sentiment:** Analyst consensus is Buy, institutional buys are ongoing, and media coverage highlights positive catalysts.  
- **Risk Profile:** High beta (~200+) signals high volatility; investors should be comfortable with swings in price.

**Bottom line:** For investors willing to accept medium–high volatility, Lam Research presents a compelling growth opportunity with strong earnings, solid fundamentals, and a bullish technical stance.

**Disclaimer:** This report is for informational purposes only and does not constitute financial advice. Investment involves risk.